Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and ...
GIMOTI leverages nasal delivery to capture the expanding diabetic gastroparesis market due to growing diabetes prevalence. Its advantages over oral therapies, strong sales growth, expanding prescriber ...
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed stomach emptying, leading to symptoms such as early satiety, upper abdominal pain, nausea, vomiting, and a persistent ...
(MENAFN- GetNews) The Key Gastroparesis Companies in the market include - CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda ...
Differing professional viewpoints, a lack of diagnostic standards, and regulatory roadblocks to new medications are among the factors hindering progress in treating people with gastroparesis, but ...
Please provide your email address to receive an email when new articles are posted on . The evidence base was not sufficient to recommend many of the common treatments for gastroparesis. Public ...
HealthDay News — In a clinical practice guideline issued by the American Gastroenterological Association and published in the October issue of Gastroenterology, conditional recommendations are ...
For individuals with suspected gastroparesis, a conditional recommendation was made against using 2-hour gastric emptying testing and in favor of 4-hour testing. HealthDay News — In a clinical ...
A NEW study from Cairo University Hospital provides fresh clinical insights into the diagnosis and management of diabetic gastroparesis (GP), a debilitating complication of long-standing diabetes ...
Gastroparesis affects thousands of people, often causing nausea, postprandial fullness, vomiting, discomfort, and major disruptions to quality of life. Bethesda, MD (Sept. 17, 2025) — The American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results